טוען...
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
The majority of patients with newly diagnosed chronic myeloid leukemia (CML) will enjoy a life expectancy equivalent to that of unaffected individuals, but will remain on life-long treatment with a concomitant requirement for on-going hospital interactions for molecular monitoring and drug dispensin...
שמור ב:
| הוצא לאור ב: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ferrata Storti Foundation
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6821602/ https://ncbi.nlm.nih.gov/pubmed/30923102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.214809 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|